VivoSeq
Other

Premature Infants

0

Pipeline Programs

5

Active Trials

1

Companies Involved

Premature Infants is an early-stage landscape with 0 programs across 1 company. The most active players are Johnson & Johnson Pharmaceutical Research & Development, L.L.C..

Pipeline Metrics

Competitive Density

19/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

81/100

Attrition Rate

14/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

35

clinical trials

Completed21 · 60%
Terminated5 · 14%
Unknown status4 · 11%
Not yet recruiting2 · 6%
Enrolling by invitation2 · 6%
Recruiting1 · 3%

Trial Activity

35 trials

Prophylactic IV Paracetamol in Extremely Premature Infants
Enrolling by invitation··Phase 2/3·NCT07067177·28 enrolled
Metronidazole Pharmacokinetics (PK) in Premature Infants
Completed··Phase 1·NCT01222585·24 enrolled
Ibuprofen and Renal Function in Premature Infants
Completed··Phase 4·NCT00217191·120 enrolled
Lactulose Supplementation in Premature Infants
Completed··Phase 2·NCT00616876·28 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)